Amphastar Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AMPH)

$19.26 0.66 (3.55 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$18.60
Today's Range$18.58 - $19.35
52-Week Range$12.05 - $21.75
Volume262,921 shs
Average Volume290,836 shs
Market Capitalization$848.71 million
P/E Ratio123.07
Dividend YieldN/A
Beta1.69

About Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals logoAmphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Receive AMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMPH
CUSIPN/A
Phone909-980-9484

Debt

Debt-to-Equity Ratio0.13%
Current Ratio3.08%
Quick Ratio1.86%

Price-To-Earnings

Trailing P/E Ratio123.07
Forward P/E Ratio-642.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$255.16 million
Price / Sales3.47
Cash Flow$0.57 per share
Price / Cash33.86
Book Value$7.15 per share
Price / Book2.69

Profitability

Trailing EPSN/A
Net Income$10.53 million
Net Margins0.12%
Return on Equity2.30%
Return on Assets1.74%

Miscellaneous

Employees1,541
Outstanding Shares45,980,000

Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

How will Amphastar Pharmaceuticals' stock buyback program work?

Amphastar Pharmaceuticals announced that its board has authorized a stock repurchase plan on Thursday, August 10th 2017, which authorizes the company to repurchase $20,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's leadership believes its stock is undervalued.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings results on Wednesday, November, 8th. The company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.05. The business had revenue of $57.90 million for the quarter, compared to the consensus estimate of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The company's revenue for the quarter was down 9.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.14 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

Where is Amphastar Pharmaceuticals' stock going? Where will Amphastar Pharmaceuticals' stock price be in 2017?

6 analysts have issued 1-year price objectives for Amphastar Pharmaceuticals' shares. Their forecasts range from $17.00 to $29.00. On average, they expect Amphastar Pharmaceuticals' stock price to reach $20.83 in the next year. View Analyst Ratings for Amphastar Pharmaceuticals.

What are Wall Street analysts saying about Amphastar Pharmaceuticals stock?

Here are some recent quotes from research analysts about Amphastar Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. " (10/27/2017)
  • 2. Piper Jaffray Companies analysts commented, "Amphastar reported 4Q16 diluted EPS of $0.01 on revenues of $63.5M, compared to Street estimates of ($0.01) and $55.9M, respectively. Though the base business is facing some challenges as we move further into 2017 (i.e., uncertainty over the trajectory of generic enoxaparin; the potential removal of AMPH's injectable epinephrine given that it is an unapproved product), we nonetheless remain bullish on AMPH shares, given that the pipeline continues to advance and given our view that it very much has the potential to drive transformative longer-term cash generation (AMPH also being one of the few generics companies solely focused on more complex dosage forms also doesn't hurt). We reiterate our Overweight rating and are lowering our PT to $20 from $22 (see below for more details)." (3/14/2017)
  • 3. BMO Capital Markets analysts commented, " AMPH reported 4Q16 revenue of $63.5mm vs. BMO/consensus $56.5mm/ $55.9mm and adj. EPS of $0.01 vs. BMO/consensus $0.02/($0.01). Revenue upside was offset by lower gross margin and higher R&D. Without 2017 revenue/EPS guidance, there is some uncertainty with the numbers given a number of moving parts, including Enoxaparin sales, potential withdrawal of Epinephrine vials, overall pricing pressure, contribution from new approvals, and higher spending levels to invest in the pipeline. We are lowering estimates and our target goes to $16 from $18. The pipeline has value, but we await near-term execution." (3/14/2017)
  • 4. Needham & Company LLC analysts commented, "While AMPH reported 4Q16 results that bested the Street's expectations on both top and bottom lines, the company has taken its lumps from the FDA over the last three months. Two recent CRLs (Primatene Mist and intranasal naloxone) have delayed two branded product opportunities by at least 12 months. FDA recently requested that AMPH discontinue the distribution of its epinephrine vial product, which generated $18.6MM in 2016 revenues. The last shot on goal in terms of potential near-term approvals is an ANDA product (undisclosed injectable), which AMPH mgmt expects will make meaningful sales contributions in 2017. The ANDA product pipeline is expected to make additional contributions in 2018. We maintain our Buy rating and adjust our PT to $18 (from $20) to account for a reduction in base business revenues." (3/14/2017)

Who are some of Amphastar Pharmaceuticals' key competitors?

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the folowing people:

  • Mary Ziping Luo Ph.D., Chief Operating Officer, Chief Scientist and Chairman of the Board (Age 67)
  • Jason B. Shandell J.D., President, General Counsel, Director (Age 43)
  • Jack Yongfeng Zhang Ph.D., Chief Executive Officer, Chief Scientific Officer, Director (Age 70)
  • William J. Peters, Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc. (Age 49)
  • Diane G. Gerst, Executive Vice President - Quality Assurance and Regulatory Affairs and President of Amphastar Nanjing Pharmaceuticals Inc (Age 57)
  • Rong Zhou, Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc. (Age 58)
  • Michael A. Zasloff M.D. Ph.D., Lead Independent Director (Age 71)
  • Richard Koo CPA, Independent Director (Age 76)
  • Howard S. Lee Ph.D., Independent Director (Age 54)
  • Floyd F. Petersen, Independent Director (Age 73)

Who owns Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.39%), Bank of New York Mellon Corp (0.99%), JPMorgan Chase & Co. (0.85%), Rothschild Asset Management Inc. (0.77%), Cornerstone Capital Management Holdings LLC. (0.62%) and Principal Financial Group Inc. (0.61%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

Who sold Amphastar Pharmaceuticals stock? Who is selling Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Bank of New York Mellon Corp, Cadence Capital Management LLC, JPMorgan Chase & Co., Skandinaviska Enskilda Banken AB publ, Rothschild Asset Management Inc., California State Teachers Retirement System and Great West Life Assurance Co. Can. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Floyd F Petersen, Jason B Shandell, Michael A Zasloff, Richard K Prins, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Who bought Amphastar Pharmaceuticals stock? Who is buying Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Argent Capital Management LLC, GSA Capital Partners LLP, Fisher Asset Management LLC, Nordea Investment Management AB, SG Americas Securities LLC, BNP Paribas Arbitrage SA and Cornerstone Capital Management Holdings LLC.. View Insider Buying and Selling for Amphastar Pharmaceuticals.

How do I buy Amphastar Pharmaceuticals stock?

Shares of Amphastar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amphastar Pharmaceuticals' stock price today?

One share of Amphastar Pharmaceuticals stock can currently be purchased for approximately $19.26.

How big of a company is Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals has a market capitalization of $848.71 million and generates $255.16 million in revenue each year. Amphastar Pharmaceuticals employs 1,541 workers across the globe.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]


MarketBeat Community Rating for Amphastar Pharmaceuticals (AMPH)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  289
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amphastar Pharmaceuticals (NASDAQ:AMPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.832.83
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.83$20.33$19.83$20.17
Price Target Upside: 6.35% upside6.46% upside33.20% upside36.91% upside

Amphastar Pharmaceuticals (NASDAQ:AMPH) Consensus Price Target History

Price Target History for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ:AMPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/1/2017Needham & Company LLCBoost Price TargetBuy$20.00 -> $23.00MediumView Rating Details
11/10/2017BMO Capital MarketsBoost Price TargetMarket Perform$16.00 -> $17.00N/AView Rating Details
11/9/2017Raymond James FinancialDowngradeOutperform -> Market Perform$18.00N/AView Rating Details
10/29/2017Jefferies GroupSet Price TargetBuy$19.00N/AView Rating Details
10/22/2017Piper Jaffray CompaniesSet Price TargetBuy$19.00N/AView Rating Details
7/22/2017Wells Fargo & CompanyReiterated RatingBuyMediumView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Amphastar Pharmaceuticals (NASDAQ:AMPH) Earnings History and Estimates Chart

Earnings by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ AMPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017$0.02$0.07$57.23 million$57.90 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.06$0.11$63.40 million$65.20 millionViewListenView Earnings Details
5/8/2017Q1 2017$0.06$0.03$63.74 million$56.67 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.01)$0.01$55.78 million$63.54 millionViewN/AView Earnings Details
11/8/2016Q3$0.03$0.14$65.12 million$64.20 millionViewListenView Earnings Details
8/8/2016Q2$0.01$0.23$62.10 million$68.00 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)$0.12$62.00 million$59.40 millionViewN/AView Earnings Details
3/14/2016Q415($0.04)$0.19$64.48 million$76.90 millionViewN/AView Earnings Details
11/12/2015Q315($0.20)($0.01)$19.49 million$63.90 millionViewListenView Earnings Details
8/12/2015Q215($0.11)($0.09)$19.49 million$53.85 millionViewListenView Earnings Details
5/13/2015Q115($0.17)($0.01)$45.87 million$56.89 millionViewListenView Earnings Details
3/24/2015Q414($0.06)($0.03)$54.90 million$55.90 millionViewN/AView Earnings Details
11/12/2014Q314($0.11)($0.11)$45.89 million$59.70 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.11)$0.02$44.23 million$49.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Amphastar Pharmaceuticals (NASDAQ:AMPH) Earnings Estimates

2017 EPS Consensus Estimate: $0.41
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.09$0.09$0.09
Q2 20171$0.04$0.04$0.04
Q3 20171$0.10$0.10$0.10
Q4 20171$0.18$0.18$0.18
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Amphastar Pharmaceuticals (NASDAQ:AMPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.10%
Institutional Ownership Percentage: 44.14%
Insider Trades by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/7/2017Stephen B ShohetDirectorSell7,862$18.34$144,189.08View SEC Filing  
12/1/2017William J. PetersCFOSell6,226$19.67$122,465.42View SEC Filing  
11/30/2017Stephen B ShohetDirectorSell7,862$19.25$151,343.50View SEC Filing  
11/28/2017Diane G GerstEVPSell523$18.15$9,492.45View SEC Filing  
11/22/2017Stephen B ShohetDirectorSell7,862$18.94$148,906.28View SEC Filing  
11/21/2017Diane G GerstEVPSell523$18.81$9,837.63View SEC Filing  
11/16/2017Stephen B ShohetDirectorSell7,862$18.04$141,830.48View SEC Filing  
11/15/2017Diane G GerstEVPSell523$17.77$9,293.71View SEC Filing  
11/9/2017Stephen B ShohetDirectorSell7,862$18.55$145,840.10View SEC Filing  
11/7/2017Diane G GerstEVPSell523$17.93$9,377.39View SEC Filing  
11/2/2017Stephen B ShohetDirectorSell7,862$18.37$144,424.94View SEC Filing  
10/26/2017Stephen B ShohetDirectorSell7,862$18.39$144,582.18View SEC Filing  
10/24/2017Diane G GerstEVPSell523$18.29$9,565.67View SEC Filing  
10/19/2017Stephen B ShohetDirectorSell7,862$18.34$144,189.08View SEC Filing  
10/17/2017Diane G GerstEVPSell523$18.48$9,665.04View SEC Filing  
10/13/2017William J PetersCFOSell3,026$18.56$56,162.56View SEC Filing  
10/12/2017Stephen B ShohetDirectorSell7,862$18.73$147,255.26View SEC Filing  
10/5/2017Diane G GerstEVPSell8,444$18.87$159,338.28View SEC Filing  
10/4/2017Floyd F PetersenDirectorSell39,312$18.59$730,810.08View SEC Filing  
10/2/2017Michael A ZasloffDirectorSell63,624$18.18$1,156,684.32View SEC Filing  
8/15/2017Richard K PrinsDirectorSell10,000$14.81$148,100.00View SEC Filing  
8/14/2017Richard K PrinsDirectorSell5,000$14.80$74,000.00View SEC Filing  
6/9/2017Richard K PrinsDirectorSell10,000$17.07$170,700.00View SEC Filing  
6/1/2017Michael A ZasloffDirectorSell15,000$17.01$255,150.00View SEC Filing  
5/31/2017Jason B ShandellDirectorSell11,482$16.92$194,275.44View SEC Filing  
5/11/2017Richard K PrinsDirectorSell7,500$15.43$115,725.00View SEC Filing  
1/3/2017Floyd F PetersenDirectorSell400$18.61$7,444.00View SEC Filing  
12/15/2016Diane G GerstEVPSell2,940$20.51$60,299.40View SEC Filing  
12/5/2016Rong ZhouEVPSell61$20.70$1,262.70View SEC Filing  
12/1/2016Floyd F PetersenDirectorSell400$20.26$8,104.00View SEC Filing  
11/28/2016Jason B ShandellInsiderSell26,335$20.48$539,340.80View SEC Filing  
11/15/2016Howard LeeDirectorSell37,994$20.65$784,576.10View SEC Filing  
10/3/2016Floyd F PetersenDirectorSell400$18.75$7,500.00View SEC Filing  
9/26/2016Jason B ShandellInsiderSell56,996$19.50$1,111,422.00View SEC Filing  
9/20/2016Jack Y ZhangCEOSell444,199$21.03$9,341,504.97View SEC Filing  
9/8/2016Floyd F PetersenDirectorSell3,000$19.05$57,150.00View SEC Filing  
9/1/2016Howard LeeDirectorSell10,381$18.78$194,955.18View SEC Filing  
8/22/2016Jason B ShandellGeneral CounselSell10,000$19.95$199,500.00View SEC Filing  
8/19/2016Diane G GerstEVPSell24,046$19.28$463,606.88View SEC Filing  
8/18/2016Richard K PrinsDirectorSell3,086$19.62$60,547.32View SEC Filing  
8/17/2016Jason B ShandellInsiderSell5,987$18.86$112,914.82View SEC Filing  
8/16/2016Stephen B ShohetDirectorSell48,375$18.24$882,360.00View SEC Filing  
8/15/2016Michael A ZasloffDirectorSell48,375$18.15$878,006.25View SEC Filing  
8/12/2016William J PetersCFOSell1,027$18.19$18,681.13View SEC Filing  
8/11/2016Jason B ShandellPresidentSell5,636$18.01$101,504.36View SEC Filing  
8/11/2016Richard K PrinsDirectorSell13,993$18.03$252,293.79View SEC Filing  
7/18/2016William J PetersCFOSell2,297$17.76$40,794.72View SEC Filing  
6/15/2016Rong ZhouEVPSell1,551$15.85$24,583.35View SEC Filing  
6/13/2016Richard K PrinsDirectorSell7,500$15.94$119,550.00View SEC Filing  
6/9/2016Jason B ShandellPresidentSell9,904$16.43$162,722.72View SEC Filing  
6/2/2016William J PetersCFOSell2,297$16.00$36,752.00View SEC Filing  
5/25/2016Jason B ShandellPresidentSell1,074$15.60$16,754.40View SEC Filing  
5/18/2016Diane G GerstEVPSell1,427$13.97$19,935.19View SEC Filing  
5/17/2016Richard K PrinsDirectorSell3,200$13.56$43,392.00View SEC Filing  
4/19/2016Diane G GerstEVPSell21,244$12.89$273,835.16View SEC Filing  
4/18/2016Diane G GerstEVPSell15,637$12.83$200,622.71View SEC Filing  
3/17/2016Richard K PrinsDirectorSell2,400$11.25$27,000.00View SEC Filing  
12/17/2015Stephen B. ShohetDirectorSell30,770$14.19$436,626.30View SEC Filing  
12/16/2015Howard LeeDirectorSell38,462$14.34$551,545.08View SEC Filing  
12/16/2015Rong ZhouEVPSell772$14.29$11,031.88View SEC Filing  
12/11/2015Jack Y ZhangCEOSell63,300$14.25$902,025.00View SEC Filing  
12/8/2015Jack Y ZhangCEOSell68,117$14.71$1,002,001.07View SEC Filing  
12/3/2015Jack Y ZhangCEOSell38,583$15.45$596,107.35View SEC Filing  
8/18/2015Richard K PrinsDirectorSell9,100$14.66$133,406.00View SEC Filing  
8/17/2015Richard K. PrinsDirectorSell5,400$14.70$79,380.00View SEC Filing  
7/17/2015Michael A ZasloffDirectorSell7,692$17.41$133,917.72View SEC Filing  
6/17/2015Rong ZhouEVPSell1,000$16.48$16,480.00View SEC Filing  
6/15/2015Jack Y ZhangCEOSell45,382$16.29$739,272.78View SEC Filing  
6/12/2015Jack Y ZhangCEOSell160,495$16.23$2,604,833.85View SEC Filing  
6/9/2015Jack Y ZhangCEOSell193,758$16.43$3,183,443.94View SEC Filing  
5/22/2015Richard K PrinsDirectorSell29,452$14.77$435,006.04View SEC Filing  
5/19/2015Richard K PrinsDirectorSell3,000$14.94$44,820.00View SEC Filing  
4/9/2015Marilyn J PurchaseVPSell28,000$15.79$442,120.00View SEC Filing  
4/8/2015Diane G GerstSVPSell10,000$15.79$157,900.00View SEC Filing  
8/25/2014Howard LeeDirectorBuy6,000$10.84$65,040.00View SEC Filing  
8/19/2014Michael A ZasloffDirectorBuy3,500$10.00$35,000.00View SEC Filing  
8/18/2014Richard K PrinsDirectorBuy4,000$10.02$40,080.00View SEC Filing  
8/15/2014Floyd F PetersenDirectorBuy3,200$10.35$33,120.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amphastar Pharmaceuticals (NASDAQ AMPH) News Headlines

Source:
DateHeadline
Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AMPH-US : December 12, 2017Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AMPH-US : December 12, 2017
finance.yahoo.com - December 12 at 11:40 AM
Amphastar Pharmaceuticals, Inc. (AMPH) Director Stephen B. Shohet Sells 7,862 SharesAmphastar Pharmaceuticals, Inc. (AMPH) Director Stephen B. Shohet Sells 7,862 Shares
www.americanbankingnews.com - December 8 at 6:20 PM
Amphastar Announces Approval for Medroxyprogesterone Acetate Injectable Suspension, USPAmphastar Announces Approval for Medroxyprogesterone Acetate Injectable Suspension, USP
finance.yahoo.com - December 8 at 11:40 AM
Amphastar Pharmaceuticals, Inc. (AMPH) CFO Sells $122,465.42 in StockAmphastar Pharmaceuticals, Inc. (AMPH) CFO Sells $122,465.42 in Stock
www.americanbankingnews.com - December 5 at 7:12 PM
 Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) Will Announce Quarterly Sales of $62.58 Million Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) Will Announce Quarterly Sales of $62.58 Million
www.americanbankingnews.com - December 2 at 1:06 PM
Amphastar Pharmaceuticals (AMPH) Price Target Raised to $23.00 at Needham & Company LLCAmphastar Pharmaceuticals (AMPH) Price Target Raised to $23.00 at Needham & Company LLC
www.americanbankingnews.com - December 1 at 8:55 AM
Stephen B. Shohet Sells 7,862 Shares of Amphastar Pharmaceuticals, Inc. (AMPH) StockStephen B. Shohet Sells 7,862 Shares of Amphastar Pharmaceuticals, Inc. (AMPH) Stock
www.americanbankingnews.com - November 30 at 10:34 PM
Amphastar Pharmaceuticals, Inc. (AMPH) Given Average Recommendation of "Hold" by BrokeragesAmphastar Pharmaceuticals, Inc. (AMPH) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 30 at 7:46 PM
Amphastar Pharma (AMPH) Announces FDA Approval for Medroxyprogesterone Acetate Injectable Suspension, USP - StreetInsider.comAmphastar Pharma (AMPH) Announces FDA Approval for Medroxyprogesterone Acetate Injectable Suspension, USP - StreetInsider.com
www.streetinsider.com - November 30 at 3:34 PM
Zacks: Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) Will Post Earnings of -$0.04 Per ShareZacks: Brokerages Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) Will Post Earnings of -$0.04 Per Share
www.americanbankingnews.com - November 30 at 1:26 AM
Amphastar Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMPH) : November 29, 2017Amphastar Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMPH) : November 29, 2017
finance.yahoo.com - November 29 at 3:34 PM
Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : November 28, 2017Amphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : November 28, 2017
finance.yahoo.com - November 28 at 8:47 AM
What You Must Know About Amphastar Pharmaceuticals Inc’s (AMPH) 0.09% ROEWhat You Must Know About Amphastar Pharmaceuticals Inc’s (AMPH) 0.09% ROE
finance.yahoo.com - November 24 at 11:46 AM
Insider Selling: Amphastar Pharmaceuticals, Inc. (AMPH) Director Sells 7,862 Shares of StockInsider Selling: Amphastar Pharmaceuticals, Inc. (AMPH) Director Sells 7,862 Shares of Stock
www.americanbankingnews.com - November 17 at 10:48 PM
Pacira Announces FDA Advisory Committee Meeting To Review SNDA For EXPAREL® As A Nerve Block For Regional AnalgesiaPacira Announces FDA Advisory Committee Meeting To Review SNDA For EXPAREL® As A Nerve Block For Regional Analgesia
www.thestreet.com - November 14 at 4:21 PM
Amphastar Pharmaceuticals, Inc. (AMPH) Expected to Announce Quarterly Sales of $69.05 MillionAmphastar Pharmaceuticals, Inc. (AMPH) Expected to Announce Quarterly Sales of $69.05 Million
www.americanbankingnews.com - November 13 at 6:54 PM
FY2020 Earnings Estimate for Amphastar Pharmaceuticals, Inc. Issued By Jefferies Group (AMPH)FY2020 Earnings Estimate for Amphastar Pharmaceuticals, Inc. Issued By Jefferies Group (AMPH)
www.americanbankingnews.com - November 13 at 10:30 AM
Amphastar Pharmaceuticals, Inc. (AMPH) Given New $17.00 Price Target at BMO Capital MarketsAmphastar Pharmaceuticals, Inc. (AMPH) Given New $17.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - November 12 at 10:30 AM
Zacks: Analysts Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) to Post $0.04 Earnings Per ShareZacks: Analysts Anticipate Amphastar Pharmaceuticals, Inc. (AMPH) to Post $0.04 Earnings Per Share
www.americanbankingnews.com - November 11 at 11:12 AM
Amphastar Pharmaceuticals (AMPH) PT Raised to $17 at BMO Capital on 3Q Report; Awaiting Execution With Key ... - StreetInsider.comAmphastar Pharmaceuticals (AMPH) PT Raised to $17 at BMO Capital on 3Q Report; 'Awaiting Execution With Key ... - StreetInsider.com
www.streetinsider.com - November 11 at 9:06 AM
Pacira Pharmaceuticals To Present At Two November Healthcare ConferencesPacira Pharmaceuticals To Present At Two November Healthcare Conferences
www.thestreet.com - November 10 at 7:21 PM
Edited Transcript of AMPH earnings conference call or presentation 8-Nov-17 10:00pm GMTEdited Transcript of AMPH earnings conference call or presentation 8-Nov-17 10:00pm GMT
finance.yahoo.com - November 10 at 2:19 PM
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2017 - GlobeNewswire (press release)Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2017 - GlobeNewswire (press release)
globenewswire.com - November 9 at 4:54 PM
Amphastar Pharmaceuticals (AMPH) Management on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAmphastar Pharmaceuticals' (AMPH) Management on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 9 at 1:54 AM
Amphastar Pharmaceuticals Reports Financial Results for the Three ... - NasdaqAmphastar Pharmaceuticals Reports Financial Results for the Three ... - Nasdaq
www.nasdaq.com - November 9 at 1:54 AM
Amphastar Pharmaceuticals, Inc. (AMPH) Posts  Earnings Results, Beats Expectations By $0.05 EPSAmphastar Pharmaceuticals, Inc. (AMPH) Posts Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - November 9 at 12:44 AM
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2017Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2017
finance.yahoo.com - November 8 at 8:53 PM
Amphastar beats Street 3Q forecastsAmphastar beats Street 3Q forecasts
finance.yahoo.com - November 8 at 8:53 PM
Should Amphastar Pharmaceuticals Inc’s (AMPH) Earnings Decline In Recent Times Worry You?Should Amphastar Pharmaceuticals Inc’s (AMPH) Earnings Decline In Recent Times Worry You?
finance.yahoo.com - November 8 at 8:53 PM
Amphastar Pharmaceuticals (AMPH) & Its Rivals Head-To-Head ComparisonAmphastar Pharmaceuticals (AMPH) & Its Rivals Head-To-Head Comparison
www.americanbankingnews.com - November 6 at 5:31 PM
Amphastar Pharmaceuticals, Inc. (AMPH) Receives Consensus Recommendation of "Hold" from BrokeragesAmphastar Pharmaceuticals, Inc. (AMPH) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 5 at 5:40 PM
Amphastar Pharmaceuticals (AMPH) & Akorn (AKRX) Financial AnalysisAmphastar Pharmaceuticals (AMPH) & Akorn (AKRX) Financial Analysis
www.americanbankingnews.com - November 4 at 1:20 AM
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2017 - GlobeNewswire (press release)Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2017 - GlobeNewswire (press release)
globenewswire.com - November 2 at 4:19 PM
ETFs with exposure to Amphastar Pharmaceuticals, Inc. : November 2, 2017ETFs with exposure to Amphastar Pharmaceuticals, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 4:18 PM
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8,Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8,
www.nasdaq.com - October 31 at 5:06 PM
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2017Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2017
finance.yahoo.com - October 31 at 5:06 PM
Amphastar Pharmaceuticals (AMPH) and Its Rivals Financial ComparisonAmphastar Pharmaceuticals (AMPH) and Its Rivals Financial Comparison
www.americanbankingnews.com - October 31 at 3:07 PM
Amphastar Pharmaceuticals (AMPH) & Its Rivals Head-To-Head ReviewAmphastar Pharmaceuticals (AMPH) & Its Rivals Head-To-Head Review
www.americanbankingnews.com - October 31 at 10:00 AM
Amphastar Pharmaceuticals, Inc. (AMPH) Downgraded to "Hold" at Zacks Investment ResearchAmphastar Pharmaceuticals, Inc. (AMPH) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 27 at 8:58 PM
Amphastar Pharmaceuticals, Inc. (AMPH) Director Sells $144,582.18 in StockAmphastar Pharmaceuticals, Inc. (AMPH) Director Sells $144,582.18 in Stock
www.americanbankingnews.com - October 26 at 8:33 PM
ETFs with exposure to Amphastar Pharmaceuticals, Inc. : October 23, 2017ETFs with exposure to Amphastar Pharmaceuticals, Inc. : October 23, 2017
finance.yahoo.com - October 23 at 4:57 PM
Amphastar Pharmaceuticals, Inc. (AMPH) Receives "Buy" Rating from Piper Jaffray CompaniesAmphastar Pharmaceuticals, Inc. (AMPH) Receives "Buy" Rating from Piper Jaffray Companies
www.americanbankingnews.com - October 22 at 6:58 AM
Amphastar Pharmaceuticals, Inc. (AMPH) Lowered to Hold at Zacks Investment ResearchAmphastar Pharmaceuticals, Inc. (AMPH) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 20 at 7:40 PM
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Rating Upgraded by Zacks Investment ResearchAmphastar Pharmaceuticals, Inc. (AMPH) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 19 at 7:36 PM
Amphastar Pharmaceuticals (AMPH) & Opko Health (OPK) Head to Head ReviewAmphastar Pharmaceuticals (AMPH) & Opko Health (OPK) Head to Head Review
www.americanbankingnews.com - October 18 at 6:20 PM
Pacira Pharmaceuticals Announces FDA Acceptance Of SNDA For EXPAREL As A Nerve Block To Produce Regional AnalgesiaPacira Pharmaceuticals Announces FDA Acceptance Of SNDA For EXPAREL As A Nerve Block To Produce Regional Analgesia
www.thestreet.com - October 18 at 5:06 PM
Head to Head Analysis: Amphastar Pharmaceuticals (AMPH) and The CompetitionHead to Head Analysis: Amphastar Pharmaceuticals (AMPH) and The Competition
www.americanbankingnews.com - October 15 at 6:30 PM
Amphastar Pharmaceuticals (AMPH) and Its Competitors Head to Head ReviewAmphastar Pharmaceuticals (AMPH) and Its Competitors Head to Head Review
www.americanbankingnews.com - October 15 at 2:22 PM
Amphastar Pharmaceuticals, Inc. (AMPH) CFO Sells $56,162.56 in StockAmphastar Pharmaceuticals, Inc. (AMPH) CFO Sells $56,162.56 in Stock
www.americanbankingnews.com - October 13 at 10:30 PM
Amphastar Pharmaceuticals, Inc. (AMPH) Given Average Rating of "Hold" by AnalystsAmphastar Pharmaceuticals, Inc. (AMPH) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 11 at 6:36 PM

SEC Filings

Amphastar Pharmaceuticals (NASDAQ:AMPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amphastar Pharmaceuticals (NASDAQ:AMPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amphastar Pharmaceuticals (NASDAQ AMPH) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.